LAMP1 Modulates CXCL10-CXCR3 Axis in Macrophage Polarization
2026-06-10
This study reveals that LAMP1 acts as a molecular switch for the CXCL10-CXCR3 axis, dictating macrophage polarization in inflammatory versus non-inflammatory states. The findings demonstrate how CXCR3 antagonism, including with AMG 487, can reprogram macrophage phenotypes and mitigate acute lung injury, offering new mechanistic insight for inflammation research.
GPC3-HSP70 mRNA Nanovaccine and PD-L1 Blockade in HCC Immuno
2026-06-09
This study introduces a nanovaccine platform encoding GPC3-derived T cell epitopes fused to HSP70, achieving robust antigen-specific immunity against hepatocellular carcinoma (HCC). The combination with anti-PD-L1 therapy leads to synergistic antitumor effects, highlighting a promising strategy for overcoming immunosuppression in advanced liver cancer.
Targeted EPO mRNA Nanoparticles Suppress Ferroptosis in SCI
2026-06-09
A recent study demonstrates that mannose-modified lipid nanoparticles can deliver human erythropoietin mRNA directly to inflammatory macrophages at spinal cord injury sites, enabling local EPO protein synthesis. This targeted approach attenuates neuroinflammation and ferroptosis, resulting in improved neurological recovery and advancing mRNA-based neurorepair strategies.
Artesunate: Applied Workflows in Cancer Research and Optimiz
2026-06-08
Artesunate, a potent artemisinin derivative, enables cutting-edge in vitro oncology research through targeted AKT/mTOR pathway inhibition and ferroptosis induction. This guide translates recent mechanistic advances and reference-driven workflows into actionable protocols and troubleshooting strategies for maximizing assay fidelity.
Methyl-β-cyclodextrin: Protocol Parameters and QC for Membra
2026-06-08
Methyl-β-cyclodextrin enables selective extraction of cholesterol and certain lipids from cellular membranes, supporting research into membrane fluidity, lipid raft disruption, and cholesterol-dependent pathways. It is designed for laboratory workflows requiring precise membrane modulation and is not suitable for diagnostic or medical use. Proper storage and solution handling are essential to maintain reagent integrity.
Wortmannin: Selective PI3K Inhibitor for Cancer and Autophag
2026-06-07
Wortmannin is a potent, selective, and irreversible PI3K inhibitor widely used in cancer and autophagy research. Its nanomolar potency and specificity make it an essential tool for dissecting PI3K/Akt/mTOR signaling pathways and related cellular processes. The compound’s benchmarked efficacy, solubility profile, and protocol parameters are well defined for academic and translational workflows.
Veratridine: Voltage-Gated Sodium Channel Opener in Action
2026-06-06
Veratridine’s precise action as a voltage-gated sodium channel opener enables robust modeling of excitotoxicity, sodium channel dynamics, and targeted chemosensitivity in both neuroscience and cancer research. APExBIO’s validated Veratridine (CAS: 71-62-5) empowers reproducible, high-fidelity results across cell, tissue, and animal workflows.
Non-Canonical Dlat-Trpv3 Thermogenesis Pathway in Obesity Co
2026-06-05
This study reveals that hyperforin activates adipose thermogenesis through a Dlat-Trpv3-AMPK pathway, independent of the traditional β3-adrenergic mechanism. The findings provide a mechanistic basis for developing safer anti-obesity strategies targeting non-canonical thermogenic signaling.
ML385: Precision NRF2 Inhibitor Strategies for Cancer & Live
2026-06-05
ML385 stands out as a selective NRF2 inhibitor, enabling researchers to dissect oxidative stress, therapeutic resistance, and ferroptosis in cancer and liver disease models. This article delivers protocol-driven insights, troubleshooting tips, and evidence-backed workflows to maximize data reliability with ML385 from APExBIO.
Berberine Hydrochloride for Metabolic Disease Research: Prot
2026-06-04
Berberine hydrochloride stands out as a multipurpose tool in metabolic and cancer research, offering robust activation of AMPK and precise modulation of lipid metabolism. Applied workflows, advanced troubleshooting, and insights from recent cardioprotection studies elevate its value for translational scientists tackling diabetes, obesity, and cardiovascular disease models.
Panobinostat (LBH589): Advanced HDACi Workflows for Cancer R
2026-06-04
Panobinostat (LBH589) empowers researchers with a potent, broad-spectrum HDAC inhibitor for dissecting apoptosis and epigenetic regulation in cancer models. This guide demystifies experimental workflows, troubleshooting, and next-level applications, integrating breakthrough mechanistic insights and real-world protocol enhancements.
Verapamil HCl in Osteoporosis and Inflammation Models: Advan
2026-06-03
Explore how Verapamil HCl, a leading L-type calcium channel blocker, advances translational research in osteoporosis and inflammatory disease models. This article uniquely deciphers recent mechanistic breakthroughs and assay implications for researchers.
SZQ-3 Chromone-Maleimide Hybrid Prevents Osteoporosis via NF
2026-06-03
This study introduces SZQ-3, a synthetic chromone–maleimide hybrid, as a novel inhibitor of NF-κB that effectively prevents postmenopausal osteoporosis by targeting mitochondrial function in bone cells. The findings highlight SZQ-3's dual action in suppressing osteoblast apoptosis and osteoclast differentiation, paving the way for safer osteoporosis therapeutics.
Tacalcitol Monohydrate Enhances 5-FU Sensitivity in CRC Cell
2026-06-02
The referenced study demonstrates that tacalcitol, a synthetic analog of vitamin D3, markedly increases the efficacy of 5-fluorouracil (5-FU) in colorectal cancer cells by downregulating thymidylate synthase via a vitamin D receptor-dependent pathway. These findings suggest a mechanistically grounded strategy to augment standard CRC chemotherapy while minimizing toxicity.
CLCC1 Identified as Key Host Factor in Herpesvirus Nuclear E
2026-06-02
A recent study uncovers the essential role of the host chloride channel CLCC1 in mediating membrane fusion during herpesvirus nuclear egress. By employing a genome-wide CRISPR screen, the authors reveal how CLCC1 loss disrupts viral capsid export and reduces viral titers, providing mechanistic insight relevant for antiviral strategies and immunomodulatory research.
464 records 16/31 page Previous Next First page 上5页 1617181920 下5页 Last page